Danish enzyme producers Chr. Hansen and Novozymes have entered into an agreement to merge, with the aim of creating a global leader in biosolutions.
Chr. Hansen develops ingredients for the food, pharmaceutical and agricultural industries, including cultures, enzymes and probiotics, while Novozymes describes itself as “the world’s largest provider of enzyme and microbial technologies”.
Ester Baiget, president and CEO of Novozymes, said: “The combination of two strategically complementary companies with a shared purpose and advanced capabilities will show the world the true power of biosolutions”.
She added: “Novozymes and Chr. Hansen share the strong conviction that our combined scale, know-how, commercial strengths and innovation excellence will drive value for our shareholders, customers and society at large by providing the sustainable solutions the world so urgently needs”.
Offering a broad “biological toolbox,” the combined company is expected to have annual revenue of approximately €3.5 billion. With around 10,000 employees, the biosolutions group will operate a global network of 23 manufacturing sites and 38 R&D and application centres.
Novo Holdings is the largest shareholder in both Novozymes and Chr. Hansen. Chairman Lars Rebien Sørensen said: “The two companies are a perfect match. Chr. Hansen with its expertise in microbials and Novozymes with its background in enzymes.”
Upon completion of the merger, Baiget will assume leadership of the combined group as CEO, while Novozymes’ current finance chief, Lars Green, will be CFO.
The merger is contingent on approvals via extraordinary general meetings of the two companies, as well as regulatory approvals. The deal is currently expected to be completed in the fourth quarter of next year or first quarter of 2024.
By Antonia Garrett Peel
Source: foodbev.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
